Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LINK Study: Dextenza for Post-CXL Inflammation and Pain
NCT04168112Phase 4Completed
- Sponsor
- SightMD
- Start
- Feb 2020
- Primary completion
- Oct 2022
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ozurdex in postoperative pain and Ocular surface inflammation, sponsored by SightMD. Primary endpoint: Change in Degree of Postoperative Pain at 4 weeks. Started Feb 2020; status: completed.
02
Drugs
ozurdex
03
Conditions
postoperative painOcular surface inflammation
Beyond the preview
Go deeper on NCT04168112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168112.